Anandamide decreases glomerular filtration rate through predominant vasodilation of efferent arterioles in rat kidneys

Yukako Koura, Atsuhiro Ichihara, Yuko Tada, Yuki Kaneshiro, Hirokazu Okada, Constance J. Temm, Matsuhiko Hayashi, Takao Saruta

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

For determining the effects of anandamide (ANA) on renal hemodynamics and microcirculation, a clearance study was performed in Sprague-Dawley rats that received injections of ANA in doses of 15, 150, and 1500 pmol/kg. At doses up to 150 pmol/g, ANA significantly decreased GFR and increased renal blood flow (RBF) without affecting mean arterial pressure (MAP). In the presence of the cannabinoid type 1 (CB1) receptor antagonist AM251, only the 15-pmol/kg dose significantly increased GFR and RBF without altering MAP, with higher doses having no effect on GFR, RBF, or MAP. By contrast, AM281, which antagonizes cannabinoid receptors nonselectively, inhibited the GFR, RBF, and MAP responses to ANA. The arteriolar responses to ANA were also assessed in vitro by the blood-perfused juxtamedullary nephron technique. Higher doses of ANA significantly increased the diameter of both afferent and efferent arterioles, whereas lower doses elicited predominant efferent arteriolar dilation. AM251 attenuated the afferent arteriolar response to ANA and inhibited the efferent arteriolar response to ANA, whereas AM281 inhibited the responses in both arterioles. The CB1 receptor mRNA was expressed in afferent arterioles, and immunohistochemical staining demonstrated the presence of CB1 receptors in both afferent and efferent arterioles. These results suggest that ANA causes afferent arteriolar dilation via both CB1 and non-CB1 receptors and greater efferent arteriolar dilation via CB1 receptors, resulting in a decreased GFR and an increased RBF without affecting MAP.

Original languageEnglish
Pages (from-to)1488-1494
Number of pages7
JournalJournal of the American Society of Nephrology
Volume15
Issue number6
DOIs
Publication statusPublished - 2004 Jun

Fingerprint

Arterioles
Glomerular Filtration Rate
Vasodilation
Kidney
Renal Circulation
Cannabinoid Receptors
Arterial Pressure
Dilatation
Cannabinoid Receptor Antagonists
anandamide
Cannabinoids
Nephrons
Microcirculation
Sprague Dawley Rats
Hemodynamics
Staining and Labeling
Messenger RNA
Injections

ASJC Scopus subject areas

  • Nephrology

Cite this

Anandamide decreases glomerular filtration rate through predominant vasodilation of efferent arterioles in rat kidneys. / Koura, Yukako; Ichihara, Atsuhiro; Tada, Yuko; Kaneshiro, Yuki; Okada, Hirokazu; Temm, Constance J.; Hayashi, Matsuhiko; Saruta, Takao.

In: Journal of the American Society of Nephrology, Vol. 15, No. 6, 06.2004, p. 1488-1494.

Research output: Contribution to journalArticle

Koura, Yukako ; Ichihara, Atsuhiro ; Tada, Yuko ; Kaneshiro, Yuki ; Okada, Hirokazu ; Temm, Constance J. ; Hayashi, Matsuhiko ; Saruta, Takao. / Anandamide decreases glomerular filtration rate through predominant vasodilation of efferent arterioles in rat kidneys. In: Journal of the American Society of Nephrology. 2004 ; Vol. 15, No. 6. pp. 1488-1494.
@article{d809e2423fea44d58c18d7a62151a85d,
title = "Anandamide decreases glomerular filtration rate through predominant vasodilation of efferent arterioles in rat kidneys",
abstract = "For determining the effects of anandamide (ANA) on renal hemodynamics and microcirculation, a clearance study was performed in Sprague-Dawley rats that received injections of ANA in doses of 15, 150, and 1500 pmol/kg. At doses up to 150 pmol/g, ANA significantly decreased GFR and increased renal blood flow (RBF) without affecting mean arterial pressure (MAP). In the presence of the cannabinoid type 1 (CB1) receptor antagonist AM251, only the 15-pmol/kg dose significantly increased GFR and RBF without altering MAP, with higher doses having no effect on GFR, RBF, or MAP. By contrast, AM281, which antagonizes cannabinoid receptors nonselectively, inhibited the GFR, RBF, and MAP responses to ANA. The arteriolar responses to ANA were also assessed in vitro by the blood-perfused juxtamedullary nephron technique. Higher doses of ANA significantly increased the diameter of both afferent and efferent arterioles, whereas lower doses elicited predominant efferent arteriolar dilation. AM251 attenuated the afferent arteriolar response to ANA and inhibited the efferent arteriolar response to ANA, whereas AM281 inhibited the responses in both arterioles. The CB1 receptor mRNA was expressed in afferent arterioles, and immunohistochemical staining demonstrated the presence of CB1 receptors in both afferent and efferent arterioles. These results suggest that ANA causes afferent arteriolar dilation via both CB1 and non-CB1 receptors and greater efferent arteriolar dilation via CB1 receptors, resulting in a decreased GFR and an increased RBF without affecting MAP.",
author = "Yukako Koura and Atsuhiro Ichihara and Yuko Tada and Yuki Kaneshiro and Hirokazu Okada and Temm, {Constance J.} and Matsuhiko Hayashi and Takao Saruta",
year = "2004",
month = "6",
doi = "10.1097/01.ASN.0000130561.82631.BC",
language = "English",
volume = "15",
pages = "1488--1494",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "6",

}

TY - JOUR

T1 - Anandamide decreases glomerular filtration rate through predominant vasodilation of efferent arterioles in rat kidneys

AU - Koura, Yukako

AU - Ichihara, Atsuhiro

AU - Tada, Yuko

AU - Kaneshiro, Yuki

AU - Okada, Hirokazu

AU - Temm, Constance J.

AU - Hayashi, Matsuhiko

AU - Saruta, Takao

PY - 2004/6

Y1 - 2004/6

N2 - For determining the effects of anandamide (ANA) on renal hemodynamics and microcirculation, a clearance study was performed in Sprague-Dawley rats that received injections of ANA in doses of 15, 150, and 1500 pmol/kg. At doses up to 150 pmol/g, ANA significantly decreased GFR and increased renal blood flow (RBF) without affecting mean arterial pressure (MAP). In the presence of the cannabinoid type 1 (CB1) receptor antagonist AM251, only the 15-pmol/kg dose significantly increased GFR and RBF without altering MAP, with higher doses having no effect on GFR, RBF, or MAP. By contrast, AM281, which antagonizes cannabinoid receptors nonselectively, inhibited the GFR, RBF, and MAP responses to ANA. The arteriolar responses to ANA were also assessed in vitro by the blood-perfused juxtamedullary nephron technique. Higher doses of ANA significantly increased the diameter of both afferent and efferent arterioles, whereas lower doses elicited predominant efferent arteriolar dilation. AM251 attenuated the afferent arteriolar response to ANA and inhibited the efferent arteriolar response to ANA, whereas AM281 inhibited the responses in both arterioles. The CB1 receptor mRNA was expressed in afferent arterioles, and immunohistochemical staining demonstrated the presence of CB1 receptors in both afferent and efferent arterioles. These results suggest that ANA causes afferent arteriolar dilation via both CB1 and non-CB1 receptors and greater efferent arteriolar dilation via CB1 receptors, resulting in a decreased GFR and an increased RBF without affecting MAP.

AB - For determining the effects of anandamide (ANA) on renal hemodynamics and microcirculation, a clearance study was performed in Sprague-Dawley rats that received injections of ANA in doses of 15, 150, and 1500 pmol/kg. At doses up to 150 pmol/g, ANA significantly decreased GFR and increased renal blood flow (RBF) without affecting mean arterial pressure (MAP). In the presence of the cannabinoid type 1 (CB1) receptor antagonist AM251, only the 15-pmol/kg dose significantly increased GFR and RBF without altering MAP, with higher doses having no effect on GFR, RBF, or MAP. By contrast, AM281, which antagonizes cannabinoid receptors nonselectively, inhibited the GFR, RBF, and MAP responses to ANA. The arteriolar responses to ANA were also assessed in vitro by the blood-perfused juxtamedullary nephron technique. Higher doses of ANA significantly increased the diameter of both afferent and efferent arterioles, whereas lower doses elicited predominant efferent arteriolar dilation. AM251 attenuated the afferent arteriolar response to ANA and inhibited the efferent arteriolar response to ANA, whereas AM281 inhibited the responses in both arterioles. The CB1 receptor mRNA was expressed in afferent arterioles, and immunohistochemical staining demonstrated the presence of CB1 receptors in both afferent and efferent arterioles. These results suggest that ANA causes afferent arteriolar dilation via both CB1 and non-CB1 receptors and greater efferent arteriolar dilation via CB1 receptors, resulting in a decreased GFR and an increased RBF without affecting MAP.

UR - http://www.scopus.com/inward/record.url?scp=2542499728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542499728&partnerID=8YFLogxK

U2 - 10.1097/01.ASN.0000130561.82631.BC

DO - 10.1097/01.ASN.0000130561.82631.BC

M3 - Article

VL - 15

SP - 1488

EP - 1494

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 6

ER -